• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Cerus Corporation

    3/5/26 5:03:03 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001459351
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CERUS CORPORATION
    SEC File Number
    000-21937
    Address of Issuer
    1220 Concord Avenue
    Suite 600
    CONCORD
    CALIFORNIA
    94520
    Phone
    (925) 288-6000
    Name of Person for Whose Account the Securities are To Be Sold
    KEVIN D GREEN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    55225113901.5619217177603/05/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/12/2024Restricted StockISSUERCheckbox not checked1213303/12/2024Not Applicable
    Common03/12/2023Restricted StockISSUERCheckbox not checked4309203/12/2023Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/05/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/14/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Kevin Dennis Green

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CERS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    1/2/25 5:46:11 PM ET
    $CERS
    EDP Services
    Technology

    Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    5/14/24 6:30:46 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Benjamin Richard J was granted 264,000 shares, increasing direct ownership by 38% to 949,775 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/4/26 8:37:44 PM ET
    $CERS
    EDP Services
    Technology

    Chief Financial Officer Green Kevin Dennis was granted 300,000 shares, increasing direct ownership by 34% to 1,187,262 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/4/26 8:36:24 PM ET
    $CERS
    EDP Services
    Technology

    President and CEO Greenman William Mariner was granted 1,200,000 shares, increasing direct ownership by 29% to 5,331,167 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/4/26 8:33:35 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

    Cerus Corporation (NASDAQ:CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components

    2/20/26 8:30:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    SEC Filings

    View All

    SEC Form 144 filed by Cerus Corporation

    144 - CERUS CORP (0001020214) (Subject)

    3/5/26 5:03:03 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 10-K filed by Cerus Corporation

    10-K - CERUS CORP (0001020214) (Filer)

    3/2/26 5:03:45 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CERUS CORP (0001020214) (Filer)

    3/2/26 4:03:18 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Cerus with a new price target

    Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

    4/12/24 8:00:30 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by BTIG Research

    BTIG Research downgraded Cerus from Buy to Neutral

    1/20/23 10:02:56 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by Stephens with a new price target

    Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

    1/17/23 7:57:35 AM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    View All

    Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

    Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

    7/2/24 4:00:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

    Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

    9/27/23 8:30:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

    Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

    7/5/22 5:00:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

    Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. "We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Fu

    11/6/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cerus Corporation

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    11/12/24 9:53:11 AM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/14/24 4:21:51 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/13/24 5:01:03 PM ET
    $CERS
    EDP Services
    Technology